ERn Financial LLC Buys 44 Shares of Stryker Co. (NYSE:SYK)

ERn Financial LLC lifted its position in shares of Stryker Co. (NYSE:SYK) by 1.0% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,649 shares of the medical technology company’s stock after acquiring an additional 44 shares during the quarter. ERn Financial LLC’s holdings in Stryker were worth $1,664,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Investment Partners Asset Management Inc. acquired a new stake in Stryker during the 1st quarter worth approximately $234,000. Wealthcare Advisory Partners LLC grew its stake in shares of Stryker by 41.4% in the first quarter. Wealthcare Advisory Partners LLC now owns 1,049 shares of the medical technology company’s stock worth $375,000 after purchasing an additional 307 shares during the last quarter. S.A. Mason LLC increased its holdings in Stryker by 1.7% in the first quarter. S.A. Mason LLC now owns 2,955 shares of the medical technology company’s stock valued at $1,058,000 after purchasing an additional 50 shares during the period. DGS Capital Management LLC bought a new position in Stryker during the 1st quarter worth $239,000. Finally, GoalVest Advisory LLC lifted its holdings in Stryker by 979.5% during the 1st quarter. GoalVest Advisory LLC now owns 1,263 shares of the medical technology company’s stock worth $452,000 after buying an additional 1,146 shares during the period. Institutional investors own 77.09% of the company’s stock.

Stryker Price Performance

SYK traded up $0.03 during trading on Thursday, reaching $340.54. 723,349 shares of the company were exchanged, compared to its average volume of 1,310,991. Stryker Co. has a 12-month low of $249.98 and a 12-month high of $361.41. The company’s 50-day moving average is $336.82 and its two-hundred day moving average is $333.01. The company has a quick ratio of 0.99, a current ratio of 1.71 and a debt-to-equity ratio of 0.56. The company has a market cap of $129.73 billion, a price-to-earnings ratio of 38.99, a P/E/G ratio of 2.67 and a beta of 0.92.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Tuesday, April 30th. The medical technology company reported $2.50 EPS for the quarter, beating the consensus estimate of $2.36 by $0.14. The firm had revenue of $5.24 billion during the quarter, compared to the consensus estimate of $5.10 billion. Stryker had a net margin of 16.03% and a return on equity of 23.05%. The business’s quarterly revenue was up 9.7% compared to the same quarter last year. During the same period last year, the firm earned $2.14 EPS. Research analysts forecast that Stryker Co. will post 11.95 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 31st. Stockholders of record on Friday, June 28th will be given a dividend of $0.80 per share. This represents a $3.20 annualized dividend and a dividend yield of 0.94%. The ex-dividend date of this dividend is Friday, June 28th. Stryker’s dividend payout ratio (DPR) is currently 36.53%.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on SYK shares. BTIG Research raised their price objective on Stryker from $366.00 to $369.00 and gave the stock a “buy” rating in a research report on Wednesday, May 1st. Royal Bank of Canada boosted their price target on shares of Stryker from $360.00 to $386.00 and gave the stock an “outperform” rating in a research report on Monday, April 15th. TD Cowen lifted their target price on shares of Stryker from $365.00 to $400.00 and gave the stock a “buy” rating in a research note on Thursday, April 11th. UBS Group raised their price objective on shares of Stryker from $339.00 to $351.00 and gave the stock a “neutral” rating in a research report on Wednesday, May 1st. Finally, Piper Sandler upped their price target on Stryker from $375.00 to $380.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 1st. Four equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $370.58.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.